iBionext

iBionext is a venture studio firm founded in 2012 and based in Paris, France. It specializes in creating and developing start-ups within the healthcare sector, with a particular emphasis on biotechnology, medical technology, e-health, and health care technology. The firm operates from a dedicated location known as “Passage de l’innovation,” where it fosters innovation and collaboration among its portfolio companies. Over the past four years, iBionext has successfully established seven companies that collectively raised over 250 million euros and generated 103 highly qualified jobs, reflecting its commitment to advancing breakthrough innovations in healthcare.

Muriel Badawi

Partner

Jean-Christophe Dantonel

Managing Partner

11 past transactions

Tilak Healthcare

Venture Round in 2023
Tilak Healthcare SAS, established in 2016 and headquartered in Paris, France, specializes in developing prescribed mobile games designed for diagnostic and rehabilitation purposes for individuals with chronic diseases. The company creates clinically validated mobile games that help patients monitor and manage their conditions in an engaging manner, thereby improving health outcomes and quality of life. Tilak's offerings include a game specifically tailored to track visual parameters relevant to patients suffering from macular diseases.

Prophesee

Series C in 2022
Prophesee SA, founded in 2014 and based in Paris, France, specializes in developing advanced machine vision sensors and systems. Renowned for its neuromorphic vision technology, the company has created a unique visual processing platform that mimics human vision by detecting events rather than capturing sequences of images. This innovative Metavision® approach enables significant advancements in speed, dynamic range, data efficiency, and power consumption, making it suitable for a variety of applications including autonomous driving, mobile devices, industrial automation, and security systems. Prophesee serves a diverse clientele across multiple sectors such as biomedical, gaming, robotics, and aerospace. The company boasts a team of over 100 engineers and holds more than 50 international patents, positioning itself as a leader in next-generation vision technologies.

Tilak Healthcare

Venture Round in 2021
Tilak Healthcare SAS, established in 2016 and headquartered in Paris, France, specializes in developing prescribed mobile games designed for diagnostic and rehabilitation purposes for individuals with chronic diseases. The company creates clinically validated mobile games that help patients monitor and manage their conditions in an engaging manner, thereby improving health outcomes and quality of life. Tilak's offerings include a game specifically tailored to track visual parameters relevant to patients suffering from macular diseases.

GrAI Matter Labs

Venture Round in 2020
GrAI Matter Labs, based in Paris with additional offices in Eindhoven and Silicon Valley, specializes in the development of ultra-low power, programmable neuromorphic computing technology that is inspired by biological neural networks. Founded in 2016, the company focuses on enhancing sensor analytics and machine learning capabilities across various devices within the Internet of Things (IoT). Its innovative processors are designed to enable autonomous navigation for vehicles, robots, and drones, as well as to integrate intelligent AI into smart homes, smartphones, and wearable health monitoring devices. GrAI Matter Labs aims to deliver efficient and responsive AI solutions that optimize energy use and enhance operational performance, thereby contributing to a future where technology seamlessly assists human activities in real time.

Chronolife

Seed Round in 2019
Chronolife is a company focused on developing innovative solutions for the continuous monitoring of multiple physiological parameters. Utilizing a proprietary algorithm known as HOTS (Hierarchy of Event-Based Time Surfaces), Chronolife aims to leverage big data analysis for real-time predictions, significantly enhancing the management of patients with chronic conditions. The company is initially concentrating on two prevalent health issues: Heart Failure and Epilepsy. By integrating artificial intelligence and advanced data fusion techniques, Chronolife enables remote monitoring and improves diagnostic capabilities in the healthcare sector, ultimately seeking to transform patient care and outcomes.

Prophesee

Series C in 2019
Prophesee SA, founded in 2014 and based in Paris, France, specializes in developing advanced machine vision sensors and systems. Renowned for its neuromorphic vision technology, the company has created a unique visual processing platform that mimics human vision by detecting events rather than capturing sequences of images. This innovative Metavision® approach enables significant advancements in speed, dynamic range, data efficiency, and power consumption, making it suitable for a variety of applications including autonomous driving, mobile devices, industrial automation, and security systems. Prophesee serves a diverse clientele across multiple sectors such as biomedical, gaming, robotics, and aerospace. The company boasts a team of over 100 engineers and holds more than 50 international patents, positioning itself as a leader in next-generation vision technologies.

GrAI Matter Labs

Series A in 2018
GrAI Matter Labs, based in Paris with additional offices in Eindhoven and Silicon Valley, specializes in the development of ultra-low power, programmable neuromorphic computing technology that is inspired by biological neural networks. Founded in 2016, the company focuses on enhancing sensor analytics and machine learning capabilities across various devices within the Internet of Things (IoT). Its innovative processors are designed to enable autonomous navigation for vehicles, robots, and drones, as well as to integrate intelligent AI into smart homes, smartphones, and wearable health monitoring devices. GrAI Matter Labs aims to deliver efficient and responsive AI solutions that optimize energy use and enhance operational performance, thereby contributing to a future where technology seamlessly assists human activities in real time.

BrainEver

Venture Round in 2018
BrainEver is a medical research company focused on developing innovative drugs for neurodegenerative disorders. Building on research by Alain Prochiantz and his team, BrainEver investigates the role of homeoproteins, which are essential for brain development and ongoing neuronal functions. The company hypothesizes that administering homeoproteins can enhance the physiological resilience of neurons and improve clinical symptoms in patients. Among its drug candidates, Engrailed 1 (BREN01) is the most advanced, aimed at treating Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS). Additionally, BrainEver is actively developing a pipeline of four more drug candidates targeting other neurodegenerative conditions, including Huntington Disease and Optic Neuropathies. Through its research and development efforts, BrainEver seeks to provide effective therapeutic options for healthcare practitioners and their patients.

Prophesee

Series B in 2018
Prophesee SA, founded in 2014 and based in Paris, France, specializes in developing advanced machine vision sensors and systems. Renowned for its neuromorphic vision technology, the company has created a unique visual processing platform that mimics human vision by detecting events rather than capturing sequences of images. This innovative Metavision® approach enables significant advancements in speed, dynamic range, data efficiency, and power consumption, making it suitable for a variety of applications including autonomous driving, mobile devices, industrial automation, and security systems. Prophesee serves a diverse clientele across multiple sectors such as biomedical, gaming, robotics, and aerospace. The company boasts a team of over 100 engineers and holds more than 50 international patents, positioning itself as a leader in next-generation vision technologies.

Tilak Healthcare

Venture Round in 2017
Tilak Healthcare SAS, established in 2016 and headquartered in Paris, France, specializes in developing prescribed mobile games designed for diagnostic and rehabilitation purposes for individuals with chronic diseases. The company creates clinically validated mobile games that help patients monitor and manage their conditions in an engaging manner, thereby improving health outcomes and quality of life. Tilak's offerings include a game specifically tailored to track visual parameters relevant to patients suffering from macular diseases.

Prophesee

Series B in 2016
Prophesee SA, founded in 2014 and based in Paris, France, specializes in developing advanced machine vision sensors and systems. Renowned for its neuromorphic vision technology, the company has created a unique visual processing platform that mimics human vision by detecting events rather than capturing sequences of images. This innovative Metavision® approach enables significant advancements in speed, dynamic range, data efficiency, and power consumption, making it suitable for a variety of applications including autonomous driving, mobile devices, industrial automation, and security systems. Prophesee serves a diverse clientele across multiple sectors such as biomedical, gaming, robotics, and aerospace. The company boasts a team of over 100 engineers and holds more than 50 international patents, positioning itself as a leader in next-generation vision technologies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.